Eficacia de una estrategia combinada para mejorar el control del colesterol unido a lipoproteínas de baja densidad en pacientes con hipercolesterolemia. Ensayo clínico aleatorizado

Párraga-Martínez, Ignacio; Escobar-Rabadán, Francisco; Rabanales-Sotos, Joseba; Lago-Deibe, Fernando; Téllez-Lapeira, Juan M; Villena-Ferrer, Alejandro; Blasco-Valle, Mariano; Ferreras-Amez, José M; Morena-Rayo, Susana; Campo-del Campo, José M del; Ayuso-Raya, M Candelaria; Pérez-Pascual, José J.
Rev. esp. cardiol. (Ed. impr.) ; 71(1): 33-41, ene. 2018. graf, tab
Artículo en Español | IBECS (España) | ID: ibc-170170

Documentos relacionados

  1. The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia.
  2. Praluent (alirokumab).
  3. VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys.
  4. [First-line treatment of hypercholesterolemia : start with statin monotherapy or ezetimibe-statin combination ?]
  5. [Efficacy and safety of various doses of hybutimibe monotherapy or in combination with atorvastatin for primary hypercholesterolemia: a multicenter, randomized, double-blind, double-dummy, parallel-controlled phase Ⅲ clinical trial].
  6. Acquired low cholesterol: diagnosis and relevance to safety of low LDL therapeutic targets.
  7. Autosomal recessive hypercholesterolemia: update for 2020.
  8. Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia.
  9. Comments on the most important and recent studies involving PCSK9i.
  10. First Discovery of Cholesterol-Lowering Activity of Parthenolide as NPC1L1 Inhibitor.